CLN5 is a dubious disease in the field of genetic metabolism, clinical performance is complex and often involves multiple systems. Early identification and standardized clinical care are essential for improving prognosis. The diagnosis of CLN5 requires a combination of clinical performance, imaging, laboratory testing and pathological validation.
The platform can assist in linking a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment. Treatment and management of CLN5 requires the development of personalized treatment regimens, typically including drug therapy, rehabilitation interventions, and regular follow-up management. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many previously difficult to treat genetic metabolic diseases have been significantly improved.
Treatment needs to be closely monitored for effectiveness and adverse reactions, adapted to timely schemes according to changes in the disease. Multidisciplinary collaboration (MDT) is particularly important for the integrated management of CLN5. The platform serves China International Medical Service System, a team of domestic and foreign experts with authority in the field of genetic metabolism, who provide the following services to patients: 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.